Grant: Engage Grants Program
University of Victoria
$25,000.00
Development and optimization of quality control procedures for detection of the fish pathogen Saprolegnia parasitica in controlled trials of fish therapeutics
EF 2012-13
Résumé
Pfizer Animal Health understands the growing importance of the fish aquaculture industry in global food
production. In 2010, Pfizer acquired the Canadian company Microtek International (based in Saanichton, BC),
recognized for innovation in aquaculture vaccines research and diagnostics. This represents a continued trend
by Pfizer to enter the market of aquaculture healthcare therapeutics through the integration of leading
companies in this sector. As with any type of animal husbandry, there is the potential for disease associated
with high population densities. One major disease is Saprolegniosis, caused by the water mold Saprolegnia
parasitica in fresh water systems. This disease is a growing problem for all major aquaculture species raised in
North America and other regions. The epidemiology of this disease is poorly understood, management efforts
have encountered limited success and there is a lack of effective control measures available to fish health
specialists. Management for this disease is a challenge in both large-scale commercial operations and in
small-scale aquaculture facilities devoted to research activities and controlled vaccine trials. The presence of
this aquatic pathogen is especially problematic in such a research environment, where disease outbreaks may
interfere with experimental work, endanger stocks of valuable experimental fish and confound interpretation of
controlled trials testing therapeutics or vaccines. The ability to conduct trials and exclude disease organisms
such as S. parasitica is a critical requirement for Pfizer. To successfully complete trials and generate
acceptable data to support new product approvals, Pfizer must be able to confirm, with confidence, that the trial
system and fish are free of other infectious agents which may interfere with the trials. Our assistance with the
development and implementation of specific quality control procedures for the detection of S. parasitica will
benefit future controlled trials by Pfizer. The adoption of these procedures will improve trial efficiency and
minimize the economic loss caused by invalid trials, with the timely detection of the causal agent.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
429774-2012
Name nom
Hintz, William
Department département
Biology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
106
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Aquaculture
Area of application fr
Aquiculture
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Molecular biology
Research subject fr
Biologie moléculaire
Partie
1
Nb partie
1
Application title
Development and optimization of quality control procedures for detection of the fish pathogen Saprolegnia parasitica in controlled trials of fish therapeutics
Keyword
NSERC
Application summary
Pfizer Animal Health understands the growing importance of the fish aquaculture industry in global food
production. In 2010, Pfizer acquired the Canadian company Microtek International (based in Saanichton, BC),
recognized for innovation in aquaculture vaccines research and diagnostics. This represents a continued trend
by Pfizer to enter the market of aquaculture healthcare therapeutics through the integration of leading
companies in this sector. As with any type of animal husbandry, there is the potential for disease associated
with high population densities. One major disease is Saprolegniosis, caused by the water mold Saprolegnia
parasitica in fresh water systems. This disease is a growing problem for all major aquaculture species raised in
North America and other regions. The epidemiology of this disease is poorly understood, management efforts
have encountered limited success and there is a lack of effective control measures available to fish health
specialists. Management for this disease is a challenge in both large-scale commercial operations and in
small-scale aquaculture facilities devoted to research activities and controlled vaccine trials. The presence of
this aquatic pathogen is especially problematic in such a research environment, where disease outbreaks may
interfere with experimental work, endanger stocks of valuable experimental fish and confound interpretation of
controlled trials testing therapeutics or vaccines. The ability to conduct trials and exclude disease organisms
such as S. parasitica is a critical requirement for Pfizer. To successfully complete trials and generate
acceptable data to support new product approvals, Pfizer must be able to confirm, with confidence, that the trial
system and fish are free of other infectious agents which may interfere with the trials. Our assistance with the
development and implementation of specific quality control procedures for the detection of S. parasitica will
benefit future controlled trials by Pfizer. The adoption of these procedures will improve trial efficiency and
minimize the economic loss caused by invalid trials, with the timely detection of the causal agent.